TrialHaematologica2017

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.

John O Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.